| Date | Title | Description |
| 25.02.2025 | Pharming Technologies B.V. announces a supplement to the offer document in respect of the recommended cash offer to the shareholders of Abliva AB (publ) | Pharming Technologies B.V. announces a supplement to the offer document in respect of the recommended cash offer to the shareholders of Abliva AB (publ)
Tue, Feb 25, 2025 16:30 CET Report this content
This press release is not an offer, whe... |
| 07.02.2025 | Pharming Technologies B.V. declares unconditional and completes the recommended cash offer to the shareholders of Abliva AB (publ) and extends the acceptance period | Pharming Technologies B.V. declares unconditional and completes the recommended cash offer to the shareholders of Abliva AB (publ) and extends the acceptance period
Fri, Feb 07, 2025 22:00 CET Report this content
This press release is not a... |
| 26.08.2024 | BioStock: Abliva's CEO – We are the leading programme in mitochondrial disease | BioStock: Abliva's CEO – We are the leading programme in mitochondrial disease
Mon, Aug 26, 2024 08:46 CET Report this content
Abliva is developing drugs for the treatment of mitochondrial diseases, and the company posted positive interim p... |
| 29.05.2024 | Ablivas CEO to BioStock: “We remain on track for the interim analysis early in Q3” | Ablivas CEO to BioStock: “We remain on track for the interim analysis early in Q3”
Wed, May 29, 2024 15:14 CET Report this content
During the first quarter of 2024, Abliva focused on progressing the FALCON clinical trial towards interim ana... |
| 08.04.2024 | BioStock: Abliva’s mission to become mitochondrial medicine powerhouse | BioStock: Abliva’s mission to become mitochondrial medicine powerhouse
Mon, Apr 08, 2024 09:16 CET Report this content
Abliva’s CMO Magnus Hansson attended the 8th annual meeting of Mitochondrial Medicine – Therapeutic Development in March.... |
| 13.10.2023 | Abliva Achieves Important Milestone in the Ongoing FALCON Study | Abliva AB (Nasdaq Stockholm: ABLI) a clinical-stage company developing drugs for the treatment of rare and severe primary mitochondrial disease, today announced that the company has now included the target number of patients required for sc... |
| 05.09.2023 | Abliva’s Lead Candidate KL1333 Receives FDA Fast Track Designation | Abliva’s Lead Candidate KL1333 Receives FDA Fast Track Designation
Abliva AB (Nasdaq Stockholm: ABLI) a clinical-stage company developing drugs for the
treatment of rare and severe primary mitochondrial disease, today announced that the
... |
| 01.06.2022 | Abliva decides on a SEK 200 million financing to fund Phase 2/3 study of KL1333 to interim analysis and bring in new global life science and institutional investors
| - |
| 14.01.2022 | Resolution at the Extraordinary General Meeting in Abliva AB (publ) | Abliva AB (Nasdaq Stockholm: ABLI) (”Abliva” or the ”Company”) has today held an Extraordinary General Meeting. A summary of the resolution follows. The resolution was passed unanimously.
Approval of the Board of Directors’ resolution on a ... |
| 21.12.2021 | Notice of Extraordinary General Meeting of Abliva AB (publ) | The shareholders of Abliva AB (publ), corporate identity number 556595-6538, are hereby convened to the Extraordinary General Meeting (the “EGM”) held at 11.00 a.m. on Friday 14 January 2022 at Medicon Village, Scheeletorget 1, in Lund, Swe... |
| 21.12.2021 | Abliva resolves on directed issue of convertibles amounting to SEK 26 million | NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SWITZERLAND, THE UNITED STATES OR ANY OTHER JURISDICTION, WHERE SUCH ACTIONS ARE SUB... |
| 25.10.2021 | Abliva : Notice AGM 2021 (pdf) | Press Release
Abliva AB (publ), 556595-6538
19 April 2021 16:10:00 CEST - Lund,
Sweden
Notice of Annual General Meeting of Abliva AB (publ)
The shareholders of Abliva AB (publ), corporate identity number 556595-6538, are hereby convened to ... |
| 17.09.2021 | Abliva : to participate in World Mitochondrial Disease Week 2021 | Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage biopharmaceutical company developing medicines for the treatment of rare and severe primary mitochondrial diseases, today announces that the company will participate in World Mitochondria... |
| 19.08.2021 | Abliva : Interim Report January – June 2021 | Second quarter summary
Phase 1a/b study: positive placebo-controlled safety data for KL1333 and the first evidence of efficacy
Important events second quarter (Apr - Jun 2021)
Data from the Phase 1a/b clinical study of KL1333 was released a... |
| 20.05.2021 | ABLIVA AB (PUBL)
Abliva : Resolutions from Annual General Meeting in Abliva AB (publ) | Abliva AB (Nasdaq Stockholm: ABLI) (”Abliva” or the ”Company”) today on May 20, 2021 held its Annual General Meeting (“AGM”). Due to the continued spread of the coronavirus and the authorities’ regulations/advice on avoiding public gatherin... |
| 19.05.2021 | Abliva reports positive clinical Phase 1a/b results for KL1333 including signs of efficacy in PMD patients | Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage biopharmaceutical company developing medicines for the treatment of rare and severe primary mitochondrial diseases (PMD), today announced positive safety and pharmacokinetic data from the... |
| 06.05.2021 | ABLIVA AB (PUBL)
Abliva : Notice EGM 2021 (pdf) | Press Release
Abliva AB (publ), 556595-6538
31 March 2021 18:45:00 CEST - Lund,
Sweden
Notice of Extraordinary General Meeting of Abliva AB (publ)
The shareholders of Abliva AB (publ), 556595-6538, are hereby convened to the Extraordinary G... |
| 29.04.2021 | ABLIVA AB (PUBL)
Abliva : Resolutions at the Extraordinary General Meeting in Abliva AB (publ) | Abliva AB (Nasdaq Stockholm: ABLI) (”Abliva” or the ”Company”) has today held an Extraordinary General Meeting. Due to the continued spread of the coronavirus and the authorities’ regulations/advice on avoiding public gatherings, the Extrao... |
| 19.04.2021 | ABLIVA AB (PUBL)
Abliva : Notice of Annual General Meeting of Abliva AB (publ) | The shareholders of Abliva AB (publ), corporate identity number 556595-6538, are hereby convened to the Annual General Meeting on Thursday 20 May 2021.
Important information regarding COVID-19
Due to the continued spread of the coronavirus ... |
| 31.03.2021 | ABLIVA AB (PUBL)
Abliva : has completed a directed new issue | NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SWITZERLAND, THE UNITED STATES OR ANY OTHER JURISDICTION, WHERE SUCH ACTIONS ARE SUB... |
| 31.03.2021 | ABLIVA AB (PUBL)
Abliva : Notice of Extraordinary General Meeting of Abliva AB (publ) | The shareholders of Abliva AB (publ), 556595-6538, are hereby convened to the Extraordinary General Meeting (“EGM”) to be held on Thursday 29 April 2021.
Due to the continued spread of the coronavirus and the authorities’ regulations/advice... |
| 30.03.2021 | ABLIVA AB (PUBL)
Abliva : investigates the prerequisites for carrying out a directed new issue | NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SWITZERLAND, THE UNITED STATES OR ANY OTHER JURISDICTION, WHERE SUCH ACTIONS ARE SUB... |
| 25.03.2021 | French biotech company Step Pharma raises €35 million in Series B | Step Pharma, a Paris based biotech company, announced on 24th March 2021 that it has raised €35 million in its Series B funding round. The round was led by Sunstone Life Science Ventures and Hadean Ventures, along with participation from Ku... |
| 19.02.2021 | Abliva : Year-End Report January – December 2020 | 2020 summary
KL1333 on its way to registrational Phase 2/3 study⎢Ellen Donnelly appointed new CEO of Abliva.
Important events during 2020
KL1333
Positive feedback from the US Food and Drug Administration (“FDA”) and the UK MHRA, on the clin... |
| 19.02.2021 | ABLIVA AB (PUBL)
Abliva : Year-End Report January – December 2020 | 2020 summary
KL1333 on its way to registrational Phase 2/3 study⎢Ellen Donnelly appointed new CEO of Abliva.
Important events during 2020
KL1333
Positive feedback from the US Food and Drug Administration (“FDA”) and the UK MHRA, on the clin... |
| 21.01.2021 | Abliva appoints Ellen Donnelly as new CEO as they enter a new development stage | Abliva appoints Ellen Donnelly as new CEO as it enters a new stage in its development – Abliva |
| 12.01.2021 | ABLIVA AB (PUBL)
Abliva : Ablivas KL1333 heading for phase II/III in 2021 | 4 January, 2021
Abliva can look back on an eventful year, which was marked by the strategy shift towards treatments for mitochondrial diseases made last year. Several important milestones have been passed - including two successful rights i... |
| 12.01.2021 | Abliva : Ablivas KL1333 heading for phase II/III in 2021 | 4 January, 2021
Abliva can look back on an eventful year, which was marked by the strategy shift towards treatments for mitochondrial diseases made last year. Several important milestones have been passed - including two successful rights i... |
| 10.11.2020 | Abliva initiates a drug-drug interaction study and paves the way for a KL1333 pivotal study in 2021 | Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage biopharmaceutical company developing medicines for the treatment of rare and severe primary mitochondrial diseases, today announces dosing in the first healthy volunteers in the company’s... |
| 08.10.2020 | Abliva doses the first patient in its KL1333 Phase Ia/b clinical study | Abliva AB (Nasdaq Stockholm: ABLI) today announced that the first primary mitochondrial disease patient in the company’s ongoing KL1333 Phase Ia/b study has been dosed. In this third part of the study, the pharmaceutical properties of KL133... |
| 15.06.2020 | ABLIVA AB (PUBL)
Abliva publ : completes the directed issue of MSEK 20 to Hadean Ventures | On April 22, 2020, the Board of Directors of Abliva AB (publ) ("Abliva" or the "Company") resolved, supported by the authorization granted at the Annual General Meeting on April 25, 2019, on a directed issue of up to 27,... |
